

WHY RELYPSA IS LIKELY A ZERO: THE CHRONIC HYPERKALEMIA TREATMENT MARKET IS SMALL

June 14, 2016

RESEARCH SUMMARY

Hyperkalemia, or high potassium in the blood, is unnecessary to treat unless it's at a severe level.

Most medicare and most insurance companies don't cover Veltassa for a reason.

Veltassa is inferior to its competitor, ZS-9, because ZS-9 can treat both acute and chronic hyperkalemia patients, while Veltassa can only treat the chronic market.

Veltassa's black box label is a big drawback. There are problems with the drug and its trials, as revealed by government-funded researchers.

A potential Veltassa black swan event, And Relypsa's CEO, John Orwin's previous company's deadly drug.

Hyperkalemia, or high potassium in the blood, is unnecessary to treat unless it's at a severe level.

Most medicare and most insurance companies don't cover Veltassa for a reason.

Veltassa is inferior to its competitor, ZS-9, because ZS-9 can treat both acute and chronic hyperkalemia

patients, while Veltassa can only treat the chronic market.

Veltassa's black box label is a big drawback. There are problems with the drug and its trials, as revealed by government-funded researchers.

A potential Veltassa black swan event, And Relypsa's CEO, John Orwin's previous company's deadly drug.

Read the full report on Seeking Alpha [here](#).



Independent institutional-grade research focused on identifying asymmetric risks in small and micro-cap equities.

LEGAL DISCLAIMER

As of the publication date of our reports, White Diamond Research, along with its clients, affiliates, and related entities, may have a short position in the securities discussed and stand to realize significant gains in the event that the price of the stock declines. Use White Diamond Research at your own risk. You should do your own research and due diligence before making any investment decision. No information contained in our reports should be interpreted as financial advice.

© 2026 White Diamond Research LLC